Pregled bibliografske jedinice broj: 709642
The water-soluble triptolide derivative PG490-88 protects against cisplatin-induced acute kidney injury
The water-soluble triptolide derivative PG490-88 protects against cisplatin-induced acute kidney injury // The Journal of pharmacology and experimental therapeutics, 349 (2014), 3; 518-525 doi:10.1124/jpet.114.213769 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 709642 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The water-soluble triptolide derivative PG490-88 protects against cisplatin-induced acute kidney injury
Autori
Kim, H.J. ; Ravichandran, K. ; Ozkok. A. ; Wang. Q. ; He, Z. ; Jani, A. ; Galešić Ljubanović, Danica ; Douglas, I.S. ; Edelstein, C.L.
Izvornik
The Journal of pharmacology and experimental therapeutics (0022-3565) 349
(2014), 3;
518-525
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Triptolide derivative PG490-88; cisplatin-induced acute kidney injury
Sažetak
Triptolide, a traditional Chinese medicine, has anti-inflammatory, antiproliferative, and proapoptotic properties. As interstitial inflammation and tubular apoptosis are features of cisplatin-induced acute kidney injury (AKI), we determined the effect of the water-soluble triptolide derivative 14-succinyl triptolide sodium salt (PG490-88) in a mouse model of cisplatin-induced AKI. PG490-88 resulted in a significant decrease in blood urea nitrogen (BUN), serum creatinine, and acute tubular necrosis (ATN) score, and a nonsignificant increase in tubular apoptosis score in AKI. The mitogen-activated protein kinase (MAPK) pathway is activated in AKI. On immunoblot analysis, phosphoextracellular signal-regulated kinase (p- ERK) was increased 3.6- fold in AKI and 2.0-fold inhibited by PG490-88. Phospho-c-Jun N-terminal kinase (p-JNK) was increased in AKI. PG490-88 resulted in a nonsignificant decrease in p-JNK. Phospho-p38 was not affected by cisplatin or PG490-88. MAPK phosphatase-1 (MKP-1) that negatively regulates MAPK signaling has not previously been studied in AKI. MKP-1 activity was not affected by cisplatin or PG490-88. Changes in p-ERK, p-JNK, and MKP-1 were confirmed on reverse protein phase analysis. The ERK inhibitor U0126 resulted in lower BUN and serum creatinine, suggesting a mechanistic role of ERK in AKI. The increase in interleukin-1α (IL- 1α), IL-1β, IL-6, CXCL1, and IL-33 in the kidney in AKI was unaffected by PG490-88. In summary, PG490-88 protects against AKI and ATN despite no decrease in tubular apoptosis. The protection of PG490-88 against AKI was associated with a decrease in p-ERK and was independent of MKP-1 and proinflammatory cytokines. In conclusion, PG490-88 protects against cisplatin-induced AKI possibly by decreasing p-ERK.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
198-0000000-3355 - Značaj morfoloških čimbenika u dijagnostici, terapiji i prognozi FSGS (Galešić-Ljubanović, Danica, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Klinička bolnica "Dubrava"
Profili:
Danica Galešić Ljubanović
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE